Evidence map›Paper›PMID 22662135›Full record

ArticlePloS one2012

Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance.

Richard J Maude, Duong Socheat, Chea Nguon, Preap Saroth, Prak Dara, Guoqiao Li, Jianping Song, Shunmay Yeung, Arjen M Dondorp, Nicholas P Day and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 7 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 7 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Mass drug administration for malaria.The Cochrane database of systematic reviews · 2013
    Pooled it
  7. Pooled it
  8. Trial
  9. A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. The human malaria-Antimicrobial agents and chemotherapy · 2024
    Review
  16. Mass Drug Administration: Contextual Factor Considerations.The American journal of tropical medicine and hygiene · 2024
    Review
  17. Article
  18. Review
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 4 countries.

Richard J MaudeMahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. richardmaude@gmail.com
Duong Socheat
Chea Nguon
Preap Saroth
Prak Dara
Guoqiao Li
Jianping Song
Shunmay Yeung
Arjen M Dondorp
Nicholas P Day
Nicholas J White
Lisa J White
Cambodia National Malaria Center · KHChab Dai · KHChurchill Hospital · GBGuangzhou University of Chinese Medicine · CNLondon School of Hygiene & Tropical Medicine · GBMahidol Oxford Tropical Medicine Research Unit · THMahidol University · THUniversity of Oxford · GB

Funding

Wellcome Trust 077166/Z/05/ZWellcome Trust 089275Wellcome Trust 093956
6 · The paper itself

Abstract

backgroundMalaria elimination requires a variety of approaches individually optimized for different transmission settings. A recent field study in an area of low seasonal transmission in South West Cambodia demonstrated dramatic reductions in malaria parasite prevalence following both mass drug administration (MDA) and high treatment coverage of symptomatic patients with artemisinin-piperaquine plus primaquine. This study employed multiple combined strategies and it was unclear what contribution each made to the reductions in malaria. METHOD AND

findingsA mathematical model fitted to the trial results was used to assess the effects of the various components of these interventions, design optimal elimination strategies, and explore their interactions with artemisinin resistance, which has recently been discovered in Western Cambodia. The modelling indicated that most of the initial reduction of P. falciparum malaria resulted from MDA with artemisinin-piperaquine. The subsequent continued decline and near elimination resulted mainly from high coverage with artemisinin-piperaquine treatment. Both these strategies were more effective with the addition of primaquine. MDA with artemisinin combination therapy (ACT) increased the proportion of artemisinin resistant infections, although much less than treatment of symptomatic cases with ACT, and this increase was slowed by adding primaquine. Artemisinin resistance reduced the effectiveness of interventions using ACT when the prevalence of resistance was very high. The main results were robust to assumptions about primaquine action, and immunity.

conclusionsThe key messages of these modelling results for policy makers were: high coverage with ACT treatment can produce a long-term reduction in malaria whereas the impact of MDA is generally only short-term; primaquine enhances the effect of ACT in eliminating malaria and reduces the increase in proportion of artemisinin resistant infections; parasite prevalence is a better surveillance measure for elimination programmes than numbers of symptomatic cases; combinations of interventions are most effective and sustained efforts are crucial for successful elimination.

Indexed as

AntimalarialsArtemisininsCambodiaDrug ResistanceHumansMalaria, FalciparumModels, TheoreticalPopulation SurveillancePrevalencePrimaquineAntimalarialsartemisininArtemisininsPrimaquine

Identifiers

PMID22662135
PMCPMC3360685
OpenAlexW2062863104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.